BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ACM Global Central Laboratory Head of R&D to Present at New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs in London


2/21/2013 12:58:04 PM

Rochester, NY, Feb. 21, 2013 – ACM Global Central Laboratory, the central laboratory that continually defines the customer-service standard with its flexible approach, today announced that it will feature Head of R&D Dr. Andrew Botham as a speaker at this year’s New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs in London on February 27-28, 2013.

Dr. Andrew Botham will present, "DILI to DIOT: The early detection of drug-induced organ toxicity. Is your trial asking the right questions?" His presentation will look at drug-induced liver injury (DILI), the primary cause for post-marketing drug withdrawal and market restriction, and explore key questions around how and why DILI is missed during clinical trials. Additionally, Dr. Botham will offer new strategies for detecting other forms of drug-induced organ toxicity.

Dr. Andrew Botham is a state-registered biomedical scientist with a master’s degree in biotechnology and a PhD in medicine. He has worked within the NHS, private pharma, as well as in academic research. As the Head of R&D at ACM Global Central Laboratory, his responsibilities focus on the identification and development of new analytical practices within ACM Global, in advising project management and business development of scientific, clinical and technical aspects of all company procedures, as well as promoting and maintaining scientific excellence throughout the company.

Botham’s presentation will be held on Thursday, Feb. 28th at 9:00 a.m.

To meet with ACM Global Central Lab at New Dynamics of Biomarker Labs, Central Labs and ECG & Imaging Labs or for more information, please visit the website.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to optimize the clinical study outcomes for our clients. ACM Global performs 20 million diagnostic tests each year, offering more than 1,500 individual assays spanning virtually all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. ACM Global’s services extend to more than 60 countries, with all tests conducted and managed from central lab facilities and a seamless data management process providing a single global database.

For more information, visit www.acmgloballab.com, our Central Labs in Focus blog or call +1-866-405-0400.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES